Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

The Hydroponics Company progresses cannabis growing and distribution model

Stage I includes greenhouses for indoor cultivation and growth of medicinal cannabis.
Picture of a facility that could be used for growing plants
The first stage of its research and development facility in Queensland is completed

The Hydroponics Co Ltd (ASX:THC) has completed stage I of its research and development facility and growing capability in Queensland.

Since October 2017, the company has increased the investment in, and focus upon, the development of the Queensland site.

A premium growing facility that will focus on the production of high-quality medicinal cannabis has been established.

David Radford, chief executive officer, said: “We look forward to being granted the manufacturing licence and final approvals.

“These will allow us to commence the growing and manufacturing program of high-quality medicinal products”.

New site allows for increasing demand

The site has been developed to allow for increasing demand for high-quality medicinal cannabis products in both local and export markets.

Stage I of the development includes greenhouses for indoor cultivation and growth of medicinal cannabis.

It also has a drying and shredding facility for the initial processing of the dried plants, and an extraction laboratory for the processing of crude extract from the shredded plants.

The site will provide an onsite laboratory for the development of new strains, as well as testing and quality control of harvested products.

Vertically integrated business model

The current site, when fully optimized, will be scalable to meet the demands of a growing market.

THC plans to vertically integrate along the industry value chain by producing a high quality, processed product.

This will differentiate The Hydroponics Company from companies focused solely upon the production of medicinal cannabis as an agricultural commodity.

Stage II to focus on processing of raw material

Stage II of the company’s growth plan will focus on the processing of raw material into higher value medicinal cannabis oils for use in Australia and overseas.

These products will be provided to approved Australian patients through the National Access Cannabis (NAC) clinics in Australia as a branded product.

There will also be the opportunity to promote other premium products sourced from the company’s international partners.

Discussions have commenced with NAC Canada to supply high-quality Canndeo products to supplement NAC’s existing product portfolio.

Management is also considering an acquisition in Canada.

READ: The Hydroponics Company assesses Canadian entity with C$20 million a year in revenues

Join our Crypto, Blockchain and Cannabis Telegram group here
View full THC profile View Profile

The Hydroponics Company Ltd Timeline

Related Articles

Woman holding cannabis leaf
October 16 2018
Canadian subsidiary Crystal Mountain is expanding its range of hydroponics equipment to meet expected demand.
medical cannabis
October 01 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use